The Institute is committed to supporting the University and wider community’s efforts to understand and combat the COVID-19 pandemic. We encourage you to explore this collection of university-wide and IHSIP resources.
Boston University Community Resources
This website contains centralized information about Boston University’s plans to return students, faculty, and staff to campus.
Boston University COVID-19 Information
This central resource hosts broad information about BU updates and reporting regarding the University’s responses to and activities around COVID-19.
COVID-19 Updates for BU Researchers
Managed by the BU Office of Research, this resource compiles university updates for research teams, funding opportunities, and information from the university community on their COVID-19 related activities.
Questrom School of Business COVID-19 Information & Resource Center
The BU Questrom School of Business manages this site, which offers resources and updates about the school’s response to COVID-19.
IHSIP Webinar Discussions
Join us on Zoom for interdisciplinary conversations about COVID-19’s impact on health systems and policy.
Our updated fall offerings are on the way. Join our email list for the latest webinar news.
Did you miss a session? Access recordings of our webinars here.
Understanding Policy Driven Data Voids Through the Lenses of Operations and Disparities
One of the reasons the United States has struggled to operationalize a federally coordinated, locally executed approach to managing the COVID-19 pandemic are policy inconsistencies between federal and state agencies on data collection and reporting. Presenters Jayakanth Srinivasan, PhD and Julia Oak discussed these policy inconsistencies, and how they may exacerbate existing social inequalities and health disparities.
Digital Health Interventions for Sexual and Reproductive Health
Brian Jack, MD reviews promising digital health interventions for sexual and reproductive health, and what they reveal about principles for digital development, design approaches, and evaluation processes refined over the past decade.
Rebuilding Safety and Quality Culture in Health Systems
Join Jayakanth Srinivasan, PhD for a discussion of how workarounds, atrophy of quality and safety related organizational routines, and lack of personnel have impacted health system safety culture during the COVID-19 pandemic.
Biology, Technology, Security, and Ethics: In Pursuit of Smartphone Based COVID-19 Exposure Notification
In this session, panelists discussed the intricacies of smartphone-based exposure notification, a seemingly simple concept with deeper roots in biology, technology, security, and ethics. The presenters outlined the process and considerations as they continue to unfold to deploy their version of this technology.
Medical Product Procurement in the COVID-19 Era: Challenges & Opportunities
Based on their recent Health Affairs Blog article, Anand Devaiah, MD, FACS and Rena Conti, PhD discussed the unique challenges to supply chains and procurement ecosystems present to the United States’ efforts to combat the COVID-19 pandemic.
The Case for U.S. Health System Transformation: Response to The COVID-19 Pandemic
In the Institute’s first-ever webinar, IHSIP Director Jonathan Woodson, MD, MSS joined us to discuss how health system transformation could improve the nation’s ability to effectively combat COVID-19.
Institute Leadership Commentary
Explore analysis and commentary with contributions from IHSIP leadership.
Generic drug repurposing for COVID-19 and beyond
Alongside co-authors Susan Athey, PhD, Richard Frank, PhD, and Jonathan Gruber, PhD, Rena Conti discusses the essential role drug repurposing could play in the effort to identify COVID-19 treatment and what policymakers can do to help facilitate this essential activity.
Innovating Through Crisis: What We Should Learn from the U.S. Failure to Contain COVID-19
In this piece, Jonathan Woodson, MD, MSS reflects on the failures of U.S. leadership’s response to the pandemic, and discusses how cultivating an innovative health system might help the nation avoid this outcome in the future.
The COVID-19 Data Crisis: A Global Infodemic
Jayakanth Srinivasan, PhD discusses a basic but vital challenge health systems face across the globe face: collecting data on the virus’ spread and ensuring people have access to accurate information.
How Orphan Drug Policy Could Impede Access To COVID-19 Treatments
What happens if a drug under investigation as a COVID-19 treatment is designated as an orphan drug? Rena Conti, PhD and the University of Michigan’s Kao-Ping Chua MD, PhD discussed how this policy in Health Affairs Blog – which is meant to incentivize R&D for rare disease treatments – might impede access to a COVID-19 treatment.
Medical Product Procurement In A Time Of Federalism: The COVID-19 Challenge
IHSIP leadership Anand Devaiah, MD, FACS and Rena Conti, PhD join co-authors Michael Wijaranakula and Chinmay Kommuru in Health Affairs Blog to discuss COVID-19’s impact on medical product supply chains, as well as the U.S. federal government’s response to these challenges.
Despite The Families First Coronavirus Response Act, COVID-19 Evaluation Is Not Necessarily Free
In April, co-authors Rena Conti, PhD and the University of Michigan’s Kao-Ping Chua MD, PhD wrote to Health Affairs Blog about situations in which U.S. patients might still be responsible for paying the cost of their COVID-19 testing and care, despite the federal government’s guarantee of coverage.